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One-pot Synthesis of 4-Aminocyclohexanol Isomers by
Combining a Keto Reductase and an Amine Transaminase
Olha Sviatenko,[a] Nicolás Ríos-Lombardía,[b] Francisco Morís,[b] Javier González-Sabín,*[b]
Kollipara Venkata Manideep,[a] Simon Merdivan,[c] Sebastian Günther,[c] Philipp Süss,[d] and
Matthias Höhne*[a]
The efficient multifunctionalization by one-pot or cascade
catalytic systems has developed as an important research field,
but is often challenging due to incompatibilities or cross-
reactivities of the catalysts leading to side product formation.
Herein we report the stereoselective preparation of cis- and
trans-4-aminocyclohexanol from the potentially bio-based pre-
cursor 1,4-cyclohexanedione. We identified regio- and stereo-
selective enzymes catalyzing reduction and transamination of
the diketone, which can be performed in a one-pot sequential
or cascade mode. For this, we identified regioselective keto
reductases for the selective mono reduction of the diketone to
give 4-hydroxycyclohexanone. The system is modular and by
choosing stereocomplementary amine transaminases, both cis-
and trans-4-aminocyclohexanol were synthesized with good to
excellent diastereomeric ratios. Furthermore, we identified an
amine transaminase that produces cis-1,4-cyclohexanediamine
with diastereomeric ratios >98 :2. These examples highlight
that the high selectivity of enzymes enable short and stereo-
selective cascade multifunctionalizations to generate high-value
building blocks from renewable starting materials.
Introduction
Chiral amino alcohols are widely used as building blocks for
many pharmaceuticals such as adrenergic agents[1] or drugs
against cardiovascular, renal, and inflammatory diseases.[2] Addi-
tionally, they have also found extensive application as ligands
and chiral auxiliaries in asymmetric organic synthesis.[3] They are
exemplary for many pharmaceuticals: Their syntheses are
waste-intensive processes due to the complexity of the target
molecules and the necessity to install multiple functional
groups and two or more stereocenters in one building block.[4]
Therefore, the efficient multifunctionalization of simple starting
materials by a cascade of regio- and stereoselective reactions is
very attractive, and the development of chemoenzymatic one-
pot and tandem reactions has grown as an important research
field.[5]
In this study we focus on the synthesis of a 1,4-amino
alcohol, namely 4-aminocyclohexanol 1. A modular route giving
access to both stereoisomers is desirable: trans-1 is a valuable
precursor of drugs such as ambroxol (a secretolytic agent) and
lomibuvir (an HCV protease inhibitor),[6,7] and also of novel
bioactive molecules with a potential clinical interest.[8] Cis-1 is
required as the building block for substituted isoquinolone
derivatives[9] and certain spirocyclic compounds.[10] Although 1
is a rather simple molecule, no efficient (and highly) stereo-
selective synthesis of cis- or trans-1 has been reported: The
hydrogenation of paracetamol by applying mono- and bimet-
allic catalysts yielded 1 with cis:trans ratios of (35–51):(49–65)%
of 4-aminocyclohexanol.[13] Additionally, the ambroxol isomers
containing a cis- or trans-1 moiety were prepared starting from
cyclohexa-1,3-diene via palladium-catalyzed 1,4-diacetoxylation
and allylic substitution with the subsequent hydrogenation of
the 4-aminocylohex-2-enol moieties.[14]
Due to their excellent regio- and stereoselectivity, enzymes
as catalysts often shorten synthetic routes, as demonstrated in
the synthesis of norephedrine, where a two-step enzymatic
approach was developed as an alternative to the seven-step
classical synthesis.[15]
With these precedents in mind, we envisaged two one-pot
enzymatic procedures for the stereoselective synthesis of cis-
and trans-4-aminocyclohexanol (Scheme 1) starting from 1,4-
cyclohexanedione 2. This diketone is a very simple, symmetric
starting material that can be obtained from succinic acid,[16] a
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renewable feedstock produced by engineered E. coli cells from
biomass.[17] The first route (route A) would involve the formation
of 4-hydroxycyclohexanone 3 from diketone 2 via ketoreduc-
tase-catalyzed (KRED) monoreduction coupled with a subse-
quent transamination by an amine transaminase (ATA). The
second option (route B) is to switch the order of steps of the
previous sequential approach: a selective monoamination of 2
yields 4-aminocyclohexanone 4, followed by reduction of the
remaining carbonyl group of the intermediate to give 1. Ideally,
these sequences can be run as one-pot or cascade reaction
using stereoselective enzymes to obtain 1 in 100% theoretical
yield and without isolating any intermediate.
Although this looks straightforward, several issues have to
be addressed: The challenge of route A is to find a selective
KRED that ideally stops after one reduction step to avoid
formation of the unwanted diol side-product 5. This requires a
selective catalyst efficiently discriminating between the very
similar di- and hydroxyketones 2 and 3. To the best of our
knowledge, no efficient chemical method for the direct
selective monoreduction of 2 is available. For accessing cis-1 or
trans-1 product in the second step, stereoselective ATAs with
complementary stereopreferences have to be identified. Ideally,
the ATA would act only on the hydroxyketone 3, but not on the
diketone substrate to avoid the formation of 4 and possibly
diamine 6 as impurities. In the alternative route B, analogous
constraints on substrate- and stereoselectivities of the used
catalysts apply: ATA must convert 2, but not the amino ketone
4, to prevent formation of by-product 6; accessing cis-1 and
trans-1 in the next step requires stereoselective KREDs. Addi-
tionally, KREDs should not convert 2 to avoid hydroxyketone or
diol side products. Although water is the natural enzyme
environment, a number of challenges must be addressed to
implement such enzymatic cascades depicted in Scheme 1. For
reasons of compatibility, parameters including pH, temperature,
substrate concentration, and co-solvents must be optimized,
but also specific enzyme activities and stabilities should be
balanced and inhibition avoided.
Results and Discussion
For the first step of route A (Scheme 1), we screened 24 KREDs
from the Codexis® KRED Screening Kit and four recombinantly
expressed KREDs available in our laboratory collection with a
photometric NAD(P)H-assay employing compounds 2–4 as
substrates. Half of the enzymes converted 2 and 3 with no or
only a slight preference of the diketone 2. However, there are
also notable exceptions with significant selectivity and high
activity towards 2 (See Supporting Information). Next, suitable
hits with a preference for 2 were employed in biocatalytic
reductions of 50 mM of 2 using 2 equivalents of propan-2-ol for
cofactor recycling. We used this low excess of the electron-
donating propan-2-ol to prevent ‘over’reduction to the diol, but
still to enable full reduction of one keto-moiety to investigate
the regio selectivity of the enzymes. Three KREDs showed
excellent activity and selectivity during reduction of 2, and we
observed only small amounts of 1–4% of undesired diol 5
(Table 1, entries 1, 2 and 4). Particularly, KRED from Lactobacillus
kefir (LK-KRED) and KRED-P2-C11 (Codexis) emerged as the best
candidates leading to the highest conversions (>93%) and the
Scheme 1. A) Cyclohexane-1,4-dione 2 can be produced from bio-based
succinic acid esterified with bioethanol. B) Proposed cascades towards cis-
and trans-4-aminocyclohexanol 1. The employed enzymes keto reductase
(KRED) and amine transaminase (ATA) must be selective to avoid formation
of by-products (diol 5 and diamine 6).
Table 1. Reduction of 1,4-cyclohexanedione 2 employing KREDs.
Entry Enzyme Enz. conc.
[mg/mL]
[3][d]
[mM]
[5][d]
[mM]
1[a] LK-KRED 0.1 45.1 1.2
2[b] RR-KRED 0.27 44.6 0.8
3[c] P1-A04 0.55 37.7 5.3
4[c] P2-C11 0.04 47.2 0.5
5[c] P2-D11 0.55 36.5 1.4
[a] Reaction conditions: 2 (50 mM), 1.0 mM NAD(P)+, propan-2-ol (100 mM,
0.76% v/v), 50 mM sodium phosphate buffer, pH 7.0, 30 °C, 700 rpm, 12 h.
Lactobacillus kefir (LK)-KRED was produced in E. coli and applied as crude
cell lysate, [b] Reaction conditions: the same as in [a], except pH 8.0.
Rhodococcus ruber (RR)-KRED was produced in E. coli and applied as crude
cell lysate, [c] Reaction conditions: the same as in [a], except 125 mM
potassium phosphate buffer, 1.25 mM magnesium sulfate. Enzymes were
used as supplied in the Codexis® KRED screening kit, [d] 3 (product) and 5
(by-product) concentrations were determined by GC.
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best ratio between the target 3 and by-product 5 (entries 1 and
4).
To optimize the reduction towards high conversions, we
varied the percentage of propan-2-ol ranging from 0.76% to
40% (v/v). Interestingly, the best performances remained those
achieved with the lowest percentage of propan-2-ol as
reductant. Thus, although the ratio 3 :5 increased slightly for
LK-KRED and remarkably for KRED-P2-C11 to a higher percent-
age of the monoalcohol, the conversion gradually declined with
higher percentages of propan-2-ol (Table S7, Supporting In-
formation). It is worth highlighting not only the selectivity, but
also the high degree of conversion that is reached in the
reduction of 2 with the low propan-2-ol content of 2
equivalents, contrasting with previously reported enzymatic
keto reductions of other substrates.[18] This makes this reaction
more attractive from an economic point of view. Compared to
previous attempts, this is the first efficient enzymatic access to
produce hydroxyketone 3,[19] which itself represents a valuable
building block for syntheses of compounds against immune
disorders,[20] viral[21] and neurological[22] diseases. Compared to
our successful monoreduction of 2 (route A), no KRED was
identified having activity towards 4 which prompted us to
discard route B (Scheme 1). Alternatively, we were also able to
synthesize 3 from the diol 5 by monooxidation employing
laccases or following a recently reported methodology for the
oxidation of sterically hindered alcohols[23] with NaOCl and
AZADO, but substrate conversions were below 50% (see the SI
for full details).
After optimizing the first step of the cascade using the KREDs, we
screened our collection of 82 recombinant ATAs (wild type ATAs
and variants) towards amination of 3 using isopropylamine or
alanine as amino donors. For the pre-screening we produced ATAs
in microtiter plates and analyzed reactions by TLC with NBD  Cl
derivatization to increase sensitivity.[24] Among wild-type enzymes,
only the (S)-selective ATAs from Ruegeria pomeroyi (ATA-3HMU),
Ruegeria sp. (ATA-3FCR), and Chromobacterium violaceum (ATA-Cvi)
were able to aminate 3 (Table S1, SI). From our variant collection, 9
out of 28 variants of ATA-3FCR and ATA-3HMU converted 3
(Table S2, SI) and several variants from the ATA Vibrio fluvialis (ATA-
Vfl), despite the inactivity of the wild type (Table S1, SI).
Next, the most promising ATAs were purified (to reduce the
possibility of any unspecific reactions of cell lysate enzymes with 3)
and employed in biocatalytic reactions to analyze conversion and
stereoselectivity. Most of these ATAs afforded 1 with conversions
higher than 60% using isopropylamine (Table S4, SI). Interestingly,
all of them exhibited marked cis-selectivity. In particular, the variant
ATA-3HMU W63Y led to 92% of the cis-isomer of 1 (Table S4,
entry 12, SI), and a variant of ATA-3FCR designed for accepting
bulky substrates (ATA-3FCR-4M)[25] containing four amino acid
substitutions afforded 1 with high (>99%) cis-selectivity. Regarding
reactions with d,l-alanine as amino donor, four of the previous
enzymes were active but led to poor levels of 1 despite significant
consumption of the substrate (Table S5, SI). This substrate depletion
also occurred in the absence of an ATA, and the control reactions
revealed that the glucose dehydrogenase (used for cofactor
recycling) partially catalyzes reduction of 3 to the diol 5.
Alternatively, we assayed the panel of engineered ATAs from
Codexis® with the aim of finding a trans-selective enzyme. Most of
the ATAs turned out to be very active and catalyzed the amination
of 3 with isopropylamine with high conversion, again predom-
inantly forming the cis-isomer of 1 (Table S6, SI). For example, the
ATAs 200, 237, 251 and 254 led to cis-1 with perfect stereo-
selectivity and conversions of >95% (Table S6, entries 1, 2, 4, 5, SI).
On the other hand, only three enzymes, namely ATAs 113, 234 and
415, exhibited slight trans-selectivity (Table S6, entries 10, 17, 20,
SI), yielding 1 with cis:trans ratios of up to 3 :7.
Intrigued by our observation that most transaminases showed cis-
selectivity, we conducted molecular modeling to understand the
molecular reasons for this trend. During catalysis, 3 can be bound
to pyridoxamine-5’-phosphate in two different orientations that will
lead to the cis- or trans-configuration upon transamination. We
modeled the quinoid intermediate leading to cis-1 (Figure 1) in the
active site of the ATA-3HMU W63Y variant. The 4-hydroxyl group of
the bound 3 (modeled in both chair conformations) can be easily
solvated because it faces the solvent molecules that fill the active
site entrance tunnel. For trans-selective transamination, 3 must be
bound in a way orienting its 4-hydroxyl group towards the wall of
the active site tunnel (it would take the place of the hydrogen
atom shown in Figure 1). Then it would face the hydrophobic
amino acids L62 and F91, what impedes its solvation and thus is
energetically less favorable. Because these two residues are highly
conserved (as revealed from a multiple sequence alignment
containing >1000 proteins with sequence identities of 50–99%
with ATA-3HMU), this explains the general cis-selectivity of wild-
type PLP-fold type I ATA. Unfortunately, the amino acid sequences
of the trans-selective ATA are not known, what prevented the
construction of a model for comparison.
After the initial ATA-screening results, we aimed to increase trans-
selectivity by optimizing reaction conditions (pH, temperature,
DMSO concentration) for the two best ATA candidates 113 and 234.
Although the selectivity towards trans-1 formation increased
significantly for ATA 113 at higher pH values (Table S10, entries 1
and 3, SI), activities diminished markedly. On the contrary, ATA-234
Figure 1. Modelled quinoid intermediate in ATA-3HMU W63Y formed after
the condensation of 3 (magenta sticks) and PMP (black sticks). Subsequent
catalytic steps will lead to cis-1. Note that for obtaining the trans-isomer, 3
must bind in an orientation where its 4-hydroxyl group and 4-H atom swap
their place. This would hinder solvation of the 4-hydroxyl group. The surface
shows the active site entrance tunnel, red spheres are oxygen atoms of
water molecules (added by the YASARA program prior to energy
minimization). For a discussion of the other conformations please see the
Supporting Information and Figure S8.
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was able to keep high conversions to the product at the same level
as during the screening phase, and an improved selectivity for
trans-1 (cis/trans 20 :80). We decided to select ATA-234 for further
preparative scale experiments, as it also showed higher stability
and activity under the investigated conditions.
Once both catalytic steps were reliably established, we explored
their combination in a one-pot sequential approach. After the
reduction of 80 mg 2 by LK-KRED was completed after 24–48 h (see
SI for full details), we added the transamination reaction compo-
nents containing ATA and co-substrates and adjusted the buffer to
the previously identified pH optimum.
Pleasantly, the impact of the KRED and NADPH on the bioamination
step was negligible and the target amino alcohols cis- or trans-1
were obtained with �90% conversion (Table 2, entries 1–3). The
reaction mixtures contained small amounts (<9%) of the diol by-
product 5 and the ATAs maintained good to excellent stereo-
selectivities under the one-pot conditions, although ATA-3FCR-4 M
performed slightly better in terms of selectivity when used in an
isolated reaction. Since aminoalcohol 1 is a very hydrophilic
compound, several work-up strategies were tested for its isolation
from the aqueous medium. Commonly, derivatization with (Boc)2O
helps to increase hydrophobicity but due to high isopropylamine
concentrations would require using a large excess of the reagent.
Solid-phase extraction with Oasis WCX (weak cation exchanger) or
Sep-Pak® tC18 Silica columns was not working because 1 started to
elute from the columns already during the washing step. The
precipitation of 1 with organic acids, such as 3,3-diphenylpropionic
acid was also possible,[26] but required more optimization steps due
to high solubility of the salt. Thus, the best isolation approach was
an optimized extraction protocol and crystallization as
hydrochloride (see SI), facilitating �75% isolated yield in most
cases.[27] Product purification by column chromatography worked
best after Boc derivatization (see Supporting Information).
Importantly, the one-pot reactions were also successful if
carried out as cascade reaction. By balancing the used enzyme
amounts, diol formation could be further suppressed to 0–3%
(entries 4–6). As the tandem reactions required using one
common pH for both steps, stereoselectivities decreased for TA-
3FCR-4M and ATA-234, but not when ATA-200 was used. A
time-course analysis (Figure 2) of the reactions revealed the
following challenges of the cascade mode: As expected, the
activity of the LK-KRED for the reduction decreased after the
first 20 h of the reaction, when 90% of the diketone 2 was
converted. At the same time, the amine transaminase activity
was very low: in the beginning, the hydroxy ketone 3
accumulated and its conversion was less than 20% when 90%
of the diketone was consumed. However, the transamination
rate started to increase when the concentration of the diketone
2 was below 10 mM, indicating that 2 acted as an inhibitor of
the transaminase.
Notably, the highest stereoisomeric ratio of cis-1 of 99 :1
was obtained with ATA-200 (entry 6). Here, we did not observe
transaminase inhibition by the diketone 2, but the ATA also
formed 1,4-cyclohexanediamine 6 as by-product, as identified
by NMR. Therefore, ATA-200 gives superior results in the
sequential mode. Reaction and protein engineering might help
to increase regioselectivity for this enzyme. In summary, our
approach is the first preparation of 1,4-amino alcohols by a
two-enzyme one-pot reaction and therefore extends the
literature-known synthesis methods for obtaining 1,2-[11] and
1,3-amino alcohols.[12]
Due to its broader substrate specificity, ATA-200 can be
applied for the synthesis of the diamine 6: Starting from 80 mg
of 2, transamination furnished the diamine with nearly
quantitative conversion (entry 7). Remarkably, 1H-NMR revealed
that the cis isomer was formed with excellent cis:trans ratio of
98 :2 (Table 2, Entry 7, see Figure S23 for NMR spectra). Cis-6 is
used as building block for tyrosine kinase inhibitor synthesis[28]
and as ligand (1,4-dach) in the platinum complex kiteplatin [Pt
(1,4-dach)Cl2], which recently has been shown to be active
against colon cancer cells lines that are resistant to cisplatin
and oxaliplatin.[29] Furthermore, cis- and trans-6 are used to
modify the properties of polymers such as polyamide.[30] To the
best of our knowledge, the preparation of cis-6 by trans-
amination represents its first highly stereoselective synthesis.
The potential of ATA200 for synthesizing chiral diamines is
remarkable and will be explored in the future, as only few ATAs
are known that can form this class of compounds. One example
is a variant of the Paracoccus denitrificans transaminase that
converts the cyclic isosorbide diketone to give the diamine with
low yields.[31]
Table 2. Synthesis of cis- and trans-1 using one-pot sequential and
cascade reactions.
Entry Reaction
mode
ATA C[b]
[%]
1
cis:trans[a]
5
[%]
6
[%]
Scale
[mg]
1 sequential 3FCR-4 M[d] 91 80 :20 9 0 80
2 sequential ATA-200[f] 85 99 :1 9 6 80
3 sequential ATA-234[f] 88 20 :80 4 0 80
4 cascade 3FCR-4 M[e] 98 80 :20 2 0 160
5 cascade ATA-234[f] 89 25 :75 3 0 160
6 cascade ATA-200[f] 44 99 :1 0 48 160
7 ATA only ATA-200[f] 0 98 :2[c] 0 99 80
[a] Substrates and products, cis:trans ratios were determined with HPLC
and GC, [b] Percentage of total product (cis/trans)-1 formed from 3 as
detected by HPLC/GC, [c] Cis:trans ratio was evaluated by 1H-NMR (see SI),
[d] ATA-3FCR-4 M was produced in E. coli and applied as purified enzyme,
[e] ATA-3FCR-4 M was produced in E. coli and applied as cell lysate, [f]
Commercial ATAs were applied as lyophilized enzymes.
Figure 2. Cascade synthesis of cis-4-aminocyclohexanol employing LK-KRED
and ATA-3FCR-4M.
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Conclusions
In conclusion, we developed a totally enzymatic one-pot
synthesis of cis-1 from a potentially renewable bio-based
substrate. The molecular architecture of the active site of PLP
fold type I ATA causes their general cis-selectivity. We identified
only three trans-selective ATA variants, which also facilitated
the preparation of trans-1, although with lower stereo selectiv-
ity. Our approach is an attractive alternative to the established
3–5-step preparation of rac-1, starting from phenol or nitro-
benzene (See Scheme S2 in the Supporting Information). The
approach can be operated in sequential or in tandem mode
and represents an efficient functionalization of a simple starting
material by a sequence of precisely arranged reactions. It is a
nice example how cross-reactivity — a common challenge in
cascades — can be avoided by identifying two regioselective
enzymes that discriminate between two very similar substrates
such as the employed diketone and hydroxyketone 2 and 3.
The developed synthesis avoids intermediate product isolation,
metal catalysis, minimizes by-product formation and affords
high reaction yields.
Experimental Section
All experimental details on analytics, enzyme production and
screening, and all biocatalysis reactions are given in the Supporting
Information. Below follows a representative procedure for the
concurrent cascade synthesis of cis-4-aminocyclohexanol 1: The
reaction was performed at a 1.5 mmol scale (concentration of 1,4-
cyclohexanedione was 50 mM) in an opened one-necked flask
equipped with a magnetic stirring bar (stirring at 250 rpm) and a
thermometer (at 30 °C). Freshly isolated cell lysate of LK-KRED
(0.2 mg/mL) and ATA-200 (2 mg/mL) were added to 30 mL of
100 mM potassium phosphate buffer, pH 7.5, containing 1 mM
NADP+, 0.76% (v/v) isopropanol (100 mM), 1 mM MgCl2, 500 mM
isopropylamine, 1 mM PLP, and 2% v/v DMSO. After 48 hours, the
reaction was stopped after 44% conversion (Table 2) and the
product was isolated as described in the Supporting Information
and afforded light yellow crystals of cis-4-aminocyclohexanol
hydrochloride (99 :1% cis:trans ratio).
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